Research progress of small molecule inhibitors targeting PI3K-Akt-mTOR pathway / 中国生化药物杂志
Chinese Journal of Biochemical Pharmaceutics
; (6): 6-15, 2016.
Article
in Zh
| WPRIM
| ID: wpr-503636
Responsible library:
WPRO
ABSTRACT
Aberrant activation of the phosphatidylinositol 3-kinase(PI3K)-protein kinase B(PKB,Akt)-mammalian target of rapamycin(mTOR) pathway is commonly observed in human cancer and is critical for cell survival, proliferation and differentiation.A variety of small molecule inhibitors targeting PI3K-Akt-mTOR pathway are under clinical studies.This review will summarize the recent studies in terms of the PI3K-Akt-mTOR signaling pathway and cancer,research progress of the antitumor activity possessed by PI3K-Akt-mTOR inhibitors,as well as the recent research in the related field conducted by our group.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Biochemical Pharmaceutics
Year:
2016
Document type:
Article